Frankfurt - Delayed Quote EUR

Rhythm Pharmaceuticals, Inc. (1RV.F)

53.50
+2.50
+(4.90%)
At close: May 16 at 3:48:54 PM GMT+2
Loading Chart for 1RV.F
  • Previous Close 51.00
  • Open 53.50
  • Bid 53.50 x --
  • Ask 54.50 x --
  • Day's Range 53.50 - 53.50
  • 52 Week Range 32.20 - 62.50
  • Volume 11
  • Avg. Volume 0
  • Market Cap (intraday) 3.406B
  • Beta (5Y Monthly) 2.37
  • PE Ratio (TTM) --
  • EPS (TTM) -2.50
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

rhythmtx.com

283

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1RV.F

View More

Performance Overview: 1RV.F

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

1RV.F
0.94%
S&P 500 (^GSPC)
1.30%

1-Year Return

1RV.F
48.61%
S&P 500 (^GSPC)
12.48%

3-Year Return

1RV.F
1,541.10%
S&P 500 (^GSPC)
48.66%

5-Year Return

1RV.F
218.45%
S&P 500 (^GSPC)
108.07%

Compare To: 1RV.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1RV.F

View More

Valuation Measures

Annual
As of 5/15/2025
  • Market Cap

    3.42B

  • Enterprise Value

    3.28B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    25.72

  • Price/Book (mrq)

    191.48

  • Enterprise Value/Revenue

    26.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -123.28%

  • Return on Assets (ttm)

    -51.33%

  • Return on Equity (ttm)

    -150.20%

  • Revenue (ttm)

    136.86M

  • Net Income Avi to Common (ttm)

    -174.02M

  • Diluted EPS (ttm)

    -2.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    314.49M

  • Total Debt/Equity (mrq)

    69.65%

  • Levered Free Cash Flow (ttm)

    -96.71M

Research Analysis: 1RV.F

View More

Company Insights: 1RV.F

Research Reports: 1RV.F

View More

People Also Watch